Eiger BioPharmaceuticals, Inc. (EIGRQ)
USD 8.5
(6.25%)
USD 8.5
(6.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 53.3 Million USD | -17.94% |
| 2022 | 64.95 Million USD | 19.98% |
| 2021 | 54.14 Million USD | 10.93% |
| 2020 | 48.8 Million USD | 0.3% |
| 2019 | 48.65 Million USD | 35.71% |
| 2018 | 35.85 Million USD | 76.11% |
| 2017 | 20.36 Million USD | 1.72% |
| 2016 | 20.01 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 63.98 Million USD | -1.49% |
| 2023 Q2 | 57.06 Million USD | -10.82% |
| 2023 FY | 53.3 Million USD | -17.94% |
| 2023 Q3 | 57.25 Million USD | 0.34% |
| 2023 Q4 | 53.3 Million USD | -6.9% |
| 2022 Q3 | 65.43 Million USD | 7.69% |
| 2022 Q1 | 56.06 Million USD | 3.55% |
| 2022 FY | 64.95 Million USD | 19.98% |
| 2022 Q4 | 64.95 Million USD | -0.73% |
| 2022 Q2 | 60.76 Million USD | 8.39% |
| 2021 Q2 | 47.71 Million USD | 0.0% |
| 2021 FY | 54.14 Million USD | 10.93% |
| 2021 Q4 | 54.14 Million USD | 6.55% |
| 2021 Q3 | 50.81 Million USD | 6.5% |
| 2020 FY | 48.8 Million USD | 0.3% |
| 2019 FY | 48.65 Million USD | 35.71% |
| 2018 FY | 35.85 Million USD | 76.11% |
| 2017 FY | 20.36 Million USD | 1.72% |
| 2016 FY | 20.01 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -194209.773% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -463.125% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 26.446% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -6490.677% |
| Rebus Holdings, Inc. | 5.24 Million USD | -916.883% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 9.674% |
| Qrons Inc. | 1.48 Million USD | -3480.61% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -4247.124% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 28.851% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -119161.231% |
| Skye Bioscience, Inc. | 14.07 Million USD | -278.796% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -456.302% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -12544.461% |
| SQZ Biotechnologies Company | 50.03 Million USD | -6.527% |
| Intellipharmaceutics International Inc. | 12 Million USD | -343.884% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1284.034% |
| Mesoblast Limited | 188.44 Million USD | 71.713% |
| Marizyme, Inc. | 26.67 Million USD | -99.826% |
| Genus plc | 485 Million USD | 89.009% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -812.347% |
| Pharming Group N.V. | 244.07 Million USD | 78.16% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -2551.819% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -2018.365% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1302.763% |
| ContraFect Corporation | 32.53 Million USD | -63.859% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -2590.394% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1292.631% |
| IMV Inc. | 37.93 Million USD | -40.525% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -352.574% |
| MultiCell Technologies, Inc. | 1617.67 USD | -3295071.45% |
| ONE Bio Corp. | 27.49 Million USD | -93.866% |
| Accustem Sciences Inc. | 1.07 Million USD | -4839.128% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 31.146% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -2420.249% |
| Q BioMed Inc. | 8.13 Million USD | -555.421% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 35.727% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -935.846% |
| Biomind Labs Inc. | 1.49 Million USD | -3456.958% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 55.101% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -489.514% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -189.647% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -3617.585% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -37413.635% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -26404.604% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -827.718% |
| GB Sciences, Inc. | 5.41 Million USD | -883.931% |
| Alpha Cognition Inc. | 7.16 Million USD | -643.987% |
| HST Global, Inc. | 593.59 Thousand USD | -8880.059% |
| CSL Limited | 18.62 Billion USD | 99.714% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -4133.267% |
| Halberd Corporation | 728.71 Thousand USD | -7214.891% |
| Enzolytics Inc. | 365.26 Million USD | 85.407% |
| Agentix Corp. | 2.51 Million USD | -2023.236% |
| Resverlogix Corp. | 67.39 Million USD | 20.908% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -6255.427% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 88.02% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -3009.977% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -115.408% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -347.824% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1354.369% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1234.712% |
| Zenith Capital Corp. | 27.56 Thousand USD | -193251.228% |
| Genscript Biotech Corporation | 1.32 Billion USD | 95.98% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -22235.683% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1327.441% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -7729.368% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1865.784% |
| Kadimastem Ltd | 3.5 Million USD | -1420.885% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -79544.1% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -6.05% |
| BioStem Technologies, Inc. | 15.9 Million USD | -235.153% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -11370.866% |
| LadRx Corporation | 2.2 Million USD | -2322.373% |
| Cell Source, Inc. | 15.8 Million USD | -237.23% |
| Regen BioPharma, Inc. | 5.45 Million USD | -876.709% |
| Regen BioPharma, Inc. | 5.45 Million USD | -876.709% |
| NovAccess Global Inc. | 7.86 Million USD | -578.118% |
| Affymax, Inc. | 8.87 Million USD | -500.891% |
| Itoco Inc. | 1.65 Million USD | -3124.448% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -2498.26% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -781.22% |
| Mobile Lads Corp. | 1.31 Million USD | -3958.251% |
| CytoDyn Inc. | 127.89 Million USD | 58.321% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -127426.974% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -3303.076% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -382.604% |
| SYBLEU INC | 681.41 Thousand USD | -7722.715% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -773.58% |
| International Stem Cell Corporation | 5.27 Million USD | -910.138% |
| Bioxytran, Inc. | 3.24 Million USD | -1540.406% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -8417.775% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1054.506% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -30.025% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -139.412% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -2531.843% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -873.074% |
| Neutra Corp. | 973.52 Thousand USD | -5375.44% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -83.715% |
| PureTech Health plc | 125.58 Million USD | 57.554% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1318.771% |
| IXICO plc | 1.9 Million USD | -2705.095% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -159.657% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 48.41% |
| CSL Limited | 18.62 Billion USD | 99.714% |
| Cellectis S.A. | 249.36 Million USD | 78.624% |